Analysts at Evercore ISI assumed coverage on shares of TESARO, Inc. (NASDAQ:TSRO) in a report issued on Wednesday, The Fly reports. The brokerage set a $121.00 price target on the biopharmaceutical company’s stock. Evercore ISI’s price objective would suggest a potential upside of 7.09% from the stock’s current price.

Several other research firms have also commented on TSRO. Cann reiterated a “buy” rating and set a $199.00 price objective on shares of TESARO in a research note on Monday, June 5th. Robert W. Baird reiterated a “neutral” rating and set a $140.00 price objective (down previously from $155.00) on shares of TESARO in a research note on Thursday, August 10th. Cowen and Company reduced their price objective on shares of TESARO from $145.00 to $124.00 and set a “market perform” rating for the company in a research note on Monday, June 19th. Citigroup Inc. reiterated a “buy” rating and set a $216.00 price objective (down previously from $232.00) on shares of TESARO in a research note on Saturday, April 22nd. Finally, Morgan Stanley reiterated an “overweight” rating and set a $183.00 price objective on shares of TESARO in a research note on Thursday, August 10th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. TESARO currently has an average rating of “Buy” and an average target price of $173.83.

TESARO (NASDAQ TSRO) traded down 0.89% during trading on Wednesday, reaching $112.99. 657,306 shares of the company were exchanged. The stock’s market capitalization is $6.12 billion. TESARO has a 1-year low of $83.26 and a 1-year high of $192.94. The company’s 50-day moving average price is $128.57 and its 200-day moving average price is $148.68.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) EPS for the quarter, missing the consensus estimate of ($2.52) by $0.30. The firm had revenue of $29.50 million for the quarter, compared to the consensus estimate of $18.61 million. TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The company’s revenue was down 17.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.28) EPS. On average, equities analysts forecast that TESARO will post ($8.74) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/08/16/tesaro-inc-tsro-research-coverage-started-at-evercore-isi.html.

In other news, VP Edward C. English sold 8,500 shares of the company’s stock in a transaction on Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total value of $1,178,525.00. Following the sale, the vice president now directly owns 5,396 shares of the company’s stock, valued at approximately $748,155.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 34.60% of the stock is owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in TSRO. FMR LLC increased its stake in TESARO by 0.4% in the first quarter. FMR LLC now owns 8,043,921 shares of the biopharmaceutical company’s stock valued at $1,237,718,000 after buying an additional 32,918 shares during the period. BlackRock Inc. increased its stake in TESARO by 5.7% in the second quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock valued at $504,230,000 after buying an additional 195,590 shares during the period. Vanguard Group Inc. increased its stake in TESARO by 2.1% in the second quarter. Vanguard Group Inc. now owns 2,978,236 shares of the biopharmaceutical company’s stock valued at $416,537,000 after buying an additional 62,104 shares during the period. State Street Corp increased its stake in TESARO by 17.9% in the second quarter. State Street Corp now owns 1,168,913 shares of the biopharmaceutical company’s stock valued at $163,496,000 after buying an additional 177,057 shares during the period. Finally, BB Biotech AG increased its stake in TESARO by 6.5% in the second quarter. BB Biotech AG now owns 877,990 shares of the biopharmaceutical company’s stock valued at $122,796,000 after buying an additional 53,408 shares during the period.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

The Fly

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.